Abbott Laboratories (ABT)
- Previous Close
105.27 - Open
105.98 - Bid --
- Ask --
- Day's Range
105.41 - 107.77 - 52 Week Range
89.67 - 121.64 - Volume
10,520,073 - Avg. Volume
5,865,919 - Market Cap (intraday)
186.15B - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
33.42 - EPS (TTM)
3.21 - Earnings Date Jul 18, 2024 - Jul 22, 2024
- Forward Dividend & Yield 2.20 (2.09%)
- Ex-Dividend Date Apr 12, 2024
- 1y Target Est
126.44
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
www.abbott.comRecent News: ABT
Related Videos: ABT
Performance Overview: ABT
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABT
Valuation Measures
Market Cap
182.66B
Enterprise Value
191.01B
Trailing P/E
32.79
Forward P/E
22.83
PEG Ratio (5yr expected)
5.77
Price/Sales (ttm)
4.56
Price/Book (mrq)
4.73
Enterprise Value/Revenue
4.74
Enterprise Value/EBITDA
21.15
Financial Highlights
Profitability and Income Statement
Profit Margin
13.96%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
40.33B
Net Income Avi to Common (ttm)
5.61B
Diluted EPS (ttm)
3.21
Balance Sheet and Cash Flow
Total Cash (mrq)
7.28B
Total Debt/Equity (mrq)
40.88%
Levered Free Cash Flow (ttm)
--
Research Analysis: ABT
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: ABT
Analyst Report: Abbott Laboratories
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
RatingNeutralPrice TargetAnalyst Report: Abbott Laboratories
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
RatingNeutralPrice TargetWeekly Stock List
We see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
Analyst Report: Abbott Laboratories
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
RatingBearishPrice Target